Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Palatin Technologies, Inc. (PTNT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PTNT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -21.04% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.04 - 1.96 | Updated Date 06/3/2025 |
52 Weeks Range 0.04 - 1.96 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Palatin Technologies, Inc.
Company Overview
History and Background
Palatin Technologies, Inc. was founded in 1986. It focuses on developing targeted, receptor-specific peptide therapeutics for diseases with significant unmet medical needs and commercial potential.
Core Business Areas
- Commercial Products: Commercialization of Vyleesi, a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Research and Development: Research and development of novel peptide therapeutics for various indications, including melanocortin receptor programs.
Leadership and Structure
Carl Spana is the current President and CEO. The company has a board of directors and various management teams overseeing different aspects of the business.
Top Products and Market Share
Key Offerings
- Vyleesi (bremelanotide): Vyleesi is an injectable medication used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin licensed the North American rights to Vyleesi to Cosette Pharmaceuticals in 2022. The drug faces competition from Addyi (flibanserin). Market share data is not publicly available. Cosette Pharmaceuticals is responsible for marketing and sales.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There is a growing demand for novel therapeutics, especially in areas with unmet medical needs, such as sexual dysfunction.
Positioning
Palatin Technologies is a small-cap biotechnology company focused on developing peptide therapeutics. Their competitive advantage lies in their proprietary peptide technology and focus on specific receptor targets.
Total Addressable Market (TAM)
The TAM for HSDD therapeutics is estimated to be in the billions of dollars. Palatin Technologies, through its licensing agreement with Cosette Pharmaceuticals, aims to capture a portion of this market. Market size estimates vary and are dependent on consumer awareness and perception.
Upturn SWOT Analysis
Strengths
- Proprietary peptide technology
- Focus on receptor-specific therapeutics
- Experienced management team
- Partnership with Cosette Pharmaceuticals for Vyleesi
Weaknesses
- Limited financial resources
- Dependence on licensing agreements
- Commercialization risks associated with Vyleesi
- Small market capitalization
Opportunities
- Expansion of Vyleesi market share through effective marketing
- Development of new peptide therapeutics for other indications
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results for pipeline products
Threats
- Competition from existing and emerging therapies
- Regulatory hurdles and delays
- Unsuccessful clinical trials
- Patent expirations
- Economic downturn impacting pharmaceutical spending
Competitors and Market Share
Key Competitors
- AMAG (defunct)
Competitive Landscape
Palatin Technologies is a small biotech company and has few competitors since Cosette Pharma now owns the market share of Vyleesi.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on successful clinical trials and marketing strategies.
Future Projections: Future projections depends on clinical trial results and performance of partnered drugs.
Recent Initiatives: Partnership with Cosette Pharmaceuticals for Vyleesi commercialization is a recent strategic initiative.
Summary
Palatin Technologies is a small biotechnology company focused on developing peptide therapeutics. It partnered with Cosette Pharmaceuticals for Vyleesi, its main drug. The company's success depends on successful clinical trials, drug marketing, and securing additional partnerships. They face significant competition and financial risks, necessitating cautious evaluation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Palatin Technologies Investor Relations
- SEC Filings
- Industry Reports
- Yahoo Finance
- Company Press Releases
Disclaimers:
The data and analysis provided are for informational purposes only and do not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palatin Technologies, Inc.
Exchange NASDAQ | Headquaters Cranbury, NJ, United States | ||
IPO Launch date - | Co-Founder, President, CEO & Director Dr. Carl Spana Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://palatin.com |
Full time employees 30 | Website https://palatin.com | ||
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.